First published in 2010, the EULAR recommendations for the management of RA, the most frequent inflammatory rheumatic disease ...

Rheumatoid arthritis, also known as RA, affects an estimated 1.3 million people in the United States. Beyond this staggering statistic lies a complex reality: each person's experience with RA is ...

New research may lead to new targeted treatments for rheumatoid arthritis (RA), an autoimmune disease that causes joint inflammation and destruction. New research led by University of Colorado School ...

Medically reviewed by Jason DelCollo, DO Key Takeaways Gabapentin may help relieve severe knee osteoarthritis pain but is not effective for rheumatoid arthritis.Gabapentin can cause side effects like ...

People with rheumatoid arthritis usually depend on drugs to control pain in their joints. But this summer, the Food and Drug Administration approved a different sort of treatment. It's a device that ...

—Investigators conducted a secondary analysis of the TARGET trial to determine differences in cardiovascular risk between rheumatoid arthritis patients treated with triple therapy or tumor necrosis ...

This newly FDA-approved system offers a groundbreaking device for adults with RA. VENTURA, Calif., March 11, 2026 /PRNewswire/ -- With nearly 1.5 million Americans suffering from rheumatoid arthritis ...

Rheumatoid arthritis (RA) is a common autoimmune disease where the body's immune system mistakenly attacks the lining of its own joints, causing chronic pain, swelling, and stiffness. While there have ...

A macrophage-targeted PET/CT tracer predicts anti-TNF response in rheumatoid arthritis at baseline and four weeks, enabling ...

Upadacitinib may improve self-reported sleep quality at 3 months in patients with rheumatoid arthritis, with sustained benefits seen over the long term.

A new targeted PET/CT tracer can detect treatment response in rheumatoid arthritis patients in as little as four weeks, and potentially even at the start of treatment, according to new research ...